Efficacy and safety of torsemide versus furosemide in heart failure patients: A systematic review of randomized controlled trials

Article Medicine, General & Internal

Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure The TRANSFORM-HF Randomized Clinical Trial

Robert J. Mentz et al.

Summary: A randomized trial found that torsemide did not result in a significant difference in all-cause mortality compared with furosemide among patients hospitalized for heart failure. However, the interpretation of these findings is limited by loss to follow-up and participant crossover and nonadherence.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Global burden of heart failure: a comprehensive and updated review of epidemiology

Gianluigi Savarese et al.

Summary: Heart Failure (HF) is a multi-faceted and life-threatening syndrome with significant morbidity and mortality worldwide, affecting over 64 million people. While the incidence of HF has stabilized in industrialized countries, the prevalence is increasing due to population ageing and improved treatment. Developing countries lack substantial data on HF epidemiology, which shows different features compared to the Western world. This review provides updated estimates on global burden of HF including prevalence, incidence, outcomes, and costs.

CARDIOVASCULAR RESEARCH (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

An evaluation of torsemide in patients with heart failure and renal disease

Anthony E. Peters et al.

Summary: This narrative review covers the evidence for the use of torsemide in heart failure and renal diseases, comparing its effectiveness with furosemide and discussing the ongoing multicenter trial. Expert opinion suggests that torsemide may have favorable pharmacological properties compared to furosemide, potentially improving functional status and reducing hospitalization in heart failure patients. However, data regarding its effect on overall cardiovascular hospitalization/mortality reduction are mixed, and further randomized studies are needed to determine its potential benefits.

EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Paul A. Heidenreich et al.

Summary: This article provides an overview of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, including its aim, methods, and structure.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems